With Hopeful Interim Data, Ultragenyx Bets On GeneTx, Angelman Syndrome Candidate

 
• By Joseph Haas
  
Ultragenyx hopes it and GeneTx have found right genomic approach to Angelman syndrome
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip